End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33 CNY | +0.30% | +0.46% | -2.02% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- With an expected P/E ratio at 29.86 and 27.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.02% | 2.29B | - | ||
+2.99% | 95.18B | A- | ||
-4.34% | 37.55B | A- | ||
-10.41% | 33.75B | B- | ||
+75.79% | 28.2B | A | ||
-14.61% | 15.63B | C | ||
-3.46% | 13.63B | B- | ||
-12.31% | 11.5B | D+ | ||
+184.77% | 10.81B | D | ||
-54.13% | 9.23B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300294 Stock
- Ratings China Resources Boya Bio-pharmaceutical Group Co.,Ltd